Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis--a systematic review.

Riedemann JP, Muñoz S, Kavanaugh A.

Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S69-76. Review.

PMID:
16273788
2.
3.

Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis.

Abdel-Nasser AM, Mahmoud MH, El Mansoury TM, Osman AM.

Scand J Rheumatol. 2008 Sep-Oct;37(5):329-36. doi: 10.1080/03009740802116208.

PMID:
18666028
4.

Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis.

Meyer O, Nicaise-Roland P, Santos MD, Labarre C, Dougados M, Goupille P, Cantagrel A, Sibilia J, Combe B.

Arthritis Res Ther. 2006;8(2):R40. Epub 2006 Jan 26.

5.

Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis.

Kudo-Tanaka E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N, Harada Y, Katada Y, Ikeue H, Umeshita-Sasai M, Miyatake K, Saeki Y.

Clin Rheumatol. 2007 Oct;26(10):1627-33. Epub 2007 Feb 8.

PMID:
17286215
6.

Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis.

Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI.

BMC Musculoskelet Disord. 2007 Apr 20;8:37.

7.

Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis.

Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Rönnelid J, Rantapää-Dahlqvist S.

Arthritis Res Ther. 2011 Feb 3;13(1):R13. doi: 10.1186/ar3237.

8.

Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies.

Jaskowski TD, Hill HR, Russo KL, Lakos G, Szekanecz Z, Teodorescu M.

J Rheumatol. 2010 Aug 1;37(8):1582-8. doi: 10.3899/jrheum.091236. Epub 2010 Jun 1.

10.

Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.

Lakos G, Soós L, Fekete A, Szabó Z, Zeher M, Horváth IF, Dankó K, Kapitány A, Gyetvai A, Szegedi G, Szekanecz Z.

Clin Exp Rheumatol. 2008 Mar-Apr;26(2):253-60.

PMID:
18565246
11.

The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.

Liu X, Jia R, Zhao J, Li Z.

J Rheumatol. 2009 Jun;36(6):1136-42. doi: 10.3899/jrheum.080796. Epub 2009 May 15.

PMID:
19447936
12.

Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.

Soós L, Szekanecz Z, Szabó Z, Fekete A, Zeher M, Horváth IF, Dankó K, Kapitány A, Végvári A, Sipka S, Szegedi G, Lakos G.

J Rheumatol. 2007 Aug;34(8):1658-63. Epub 2007 Jul 1.

PMID:
17611988
13.

Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients.

Payet J, Goulvestre C, Bialé L, Avouac J, Wipff J, Job-Deslandre C, Batteux F, Dougados M, Kahan A, Allanore Y.

J Rheumatol. 2014 Dec;41(12):2395-402. doi: 10.3899/jrheum.131375. Epub 2014 Oct 1. Erratum in: J Rheumatol. 2015 Mar;42(3):558.

PMID:
25274898
14.

Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.

van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW.

Arthritis Rheum. 2004 Mar;50(3):709-15.

15.

Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays.

Vos I, Van Mol C, Trouw LA, Mahler M, Bakker JA, Van Offel J, De Clerck L, Huizinga TW.

Clin Rheumatol. 2017 Jul;36(7):1487-1492. doi: 10.1007/s10067-017-3684-8. Epub 2017 Jun 3.

16.

A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis.

Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, Bell M, Hudson M, Mathieu JP, Taillefer S, Jones N, Docherty P, Khraishi M, Markland J, Pope J, Robinson D, Smith D, Sutton E.

Clin Rheumatol. 2008 Jan;27(1):77-83. Epub 2007 Jun 15.

PMID:
17570008
17.

Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis.

Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C, Meyer O, Chollet-Martin S, Labarre C.

Scand J Rheumatol. 2004;33(4):218-20.

PMID:
15370715
18.

Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor.

Yamane T, Hashiramoto A, Tanaka Y, Tsumiyama K, Miura Y, Shiozawa K, Chihara K, Shiozawa S.

J Rheumatol. 2008 Mar;35(3):414-20. Epub 2008 Jan 15.

PMID:
18203327
19.

Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.

Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M.

Arthritis Res Ther. 2006;8(4):R119.

20.

The fibrin-derived citrullinated peptide β60-74Cit₆₀,₇₂,₇₄ bears the major ACPA epitope recognised by the rheumatoid arthritis-specific anticitrullinated fibrinogen autoantibodies and anti-CCP2 antibodies.

Cornillet M, Sebbag M, Verrouil E, Magyar A, Babos F, Ruyssen-Witrand A, Hudecz F, Cantagrel A, Serre G, Nogueira L.

Ann Rheum Dis. 2014 Jun;73(6):1246-52. doi: 10.1136/annrheumdis-2012-202868. Epub 2013 May 1.

PMID:
23636655

Supplemental Content

Support Center